Icatibant

This classification denotes an adrenergic beta-antagonist, non-steroidal anti-inflammatory agent, and antiasthmatic agent with the molecular formula C59H89N19O13S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7PG89G35Q7, chemically known as l-arginine, d-arginyl-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-d-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-l-(2alpha,3abeta,7abeta)-octahydro-1h-indole-2-carbonyl- but generally known as icatibant, which bears US NIH Compound Identifier 71364. European Medicines Agency schedules Icatibant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08104MIG. World Health Organization schedules icatibant in its Anatomical Therapeutic Chemical (ATC) Classification. ICATIBANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule icatibant under HS 29349990 and SITC 51579. As of Q4 2014, ICATIBANT remains the US FDA Preferred Term for this commodity. Icatibant bears US NLM identifiers UMLS ID C0246269 and NCI Concept Code C98883. SMILES: S1C(CC(NC(=O)CNC(=O)C2N(CC(O)C2)C(=O)C2N(CCC2)C(=O)C(NC(=O)C(N)CCC/N=C(/N)N)CCC/N=C(/N)N)C(=O)NC(C(=O)N2C(C(=O)N3C4C(CC3C(=O)NC(CCC/N=C(/N)N)C(=O)O)CCCC4)CC3C(C2)CCCC3)CO)CCC1.